Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Imai

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Plos One|November 27, 2013
Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinomaMitsuyoshi Urashima, Takanori Hama, Toshihito Suda, et al.
International Journal of Clinical Oncology|March 2, 2024
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumabMasaki Hashimoto, Wataru Fukuokaya, Takafumi Yanagisawa, et al.
Mbio|May 16, 2022
A Silent Operon of Photorhabdus luminescens Encodes a Prodrug Mimic of GTPNegar Shahsavari, Boyuan Wang, Yu Imai, et al.
Nature Chemical Biology|August 22, 2022
Evybactin is a DNA gyrase inhibitor that selectively kills Mycobacterium tuberculosisYu Imai, Glenn Hauk, Jeffrey Quigley, et al.
International Journal of Clinical Oncology|July 11, 2023
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancerKeiichiro Miyajima, Hirotaka Suzuki, Fumihiko Urabe, et al.
Clinical Genitourinary Cancer|April 4, 2026
Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With DenosumabYuzo Inaba, Fumihiko Urabe, Yu Imai, et al.
Urologic Oncology|October 8, 2025
Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI scoreYuya Iwamoto, Halle Foss, Yudai Ishiyama, et al.
Prostate International|April 11, 2025
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, et al.
Urologic Oncology|March 29, 2022
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitorsWataru Fukuokaya, Takahiro Kimura, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|April 8, 2025
Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective studyFumihiko Urabe, Yuki Taneda, Naoki Uchida, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Plos One|November 27, 2013
Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinomaMitsuyoshi Urashima, Takanori Hama, Toshihito Suda, et al.
International Journal of Clinical Oncology|March 2, 2024
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumabMasaki Hashimoto, Wataru Fukuokaya, Takafumi Yanagisawa, et al.
Mbio|May 16, 2022
A Silent Operon of Photorhabdus luminescens Encodes a Prodrug Mimic of GTPNegar Shahsavari, Boyuan Wang, Yu Imai, et al.
Nature Chemical Biology|August 22, 2022
Evybactin is a DNA gyrase inhibitor that selectively kills Mycobacterium tuberculosisYu Imai, Glenn Hauk, Jeffrey Quigley, et al.
International Journal of Clinical Oncology|July 11, 2023
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancerKeiichiro Miyajima, Hirotaka Suzuki, Fumihiko Urabe, et al.
Clinical Genitourinary Cancer|April 4, 2026
Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With DenosumabYuzo Inaba, Fumihiko Urabe, Yu Imai, et al.
Urologic Oncology|October 8, 2025
Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI scoreYuya Iwamoto, Halle Foss, Yudai Ishiyama, et al.
Prostate International|April 11, 2025
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective studyFumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, et al.
Urologic Oncology|March 29, 2022
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitorsWataru Fukuokaya, Takahiro Kimura, Kazumasa Komura, et al.
Japanese Journal of Clinical Oncology|April 8, 2025
Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective studyFumihiko Urabe, Yuki Taneda, Naoki Uchida, et al.
Pageof 8